IMR Press / FBL / Volume 23 / Issue 6 / DOI: 10.2741/4630

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Drug repurposing approaches to fight Dengue virus infection and related diseases

Show Less
1 Biological and Ecological Department (DEB), University of Tuscia, 01100 Viterbo, Italy
2 Department of Food and Drug, University of Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy
Front. Biosci. (Landmark Ed) 2018, 23(6), 997–1019;
Published: 1 January 2018

Dengue is a mosquito-borne viral disease caused by four antigenically distinct serotypes of Dengue Virus (DENV), namely DENV1-4 and is currently considered the most important arthropod-born viral disease in the world. An effective antiviral therapy to treat Dengue Virus infection is still missing and a number of replicative cycle inhibitors are currently under study. Considering the rapid spreading of DENV and the common timeframe required for bringing a new drug on the market, the repurposing of approved drugs used for different diseases to identify novel inhibitors of this pathogen represents an attractive approach for a rapid therapeutic intervention. Herein, we will describe the most recent drug repurposing approaches to fight DENV infection and their implications in antiviral drug-discovery.

Dengue virus
Neglected Diseases
Drug repurposing
Back to top